Avaant Pharmaceuticals

Avaant Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing transformative therapies for sleep-wake disorders. The company's primary focus is the development of potent and selective oral orexin 2 receptor (OX2R) agonists designed to address the underlying cause of narcolepsy and other hypersomnolence conditions. Founded by a team of industry veterans with deep expertise in sleep medicine and the orexin pathway, Avaant aims to improve the lives of patients suffering from excessive daytime sleepiness. Their lead candidate, AVNT-101, is currently undergoing early-stage clinical evaluation to establish its safety and pharmacological profile. The company is backed by leading life science investors including F-Prime Capital and Novo Holdings.